Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005986 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00005986 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota.
The verdict
NCT00005986, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy and filgrastim followed by peripheral stem cell transplantation in treating patients who have chronic myelogenous leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
- DRUG busulfan
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- DRUG recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005986
The ClinicalTrials.gov registry entry for NCT00005986 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005986 about?
NCT00005986 is a clinical study titled "Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating fac...
What is the current status of trial NCT00005986?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-08.
What interventions are being tested in trial NCT00005986?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG), busulfan (DRUG), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), recombinant interferon alfa (DRUG).
Who is sponsoring clinical trial NCT00005986?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.